Executive Summary
Chapter 1 - Introduction
Chapter 2 - Bigpharma top 50 and their dealmaking activity
Chapter 3 - Most active bigpharma dealmakers
3.1 Bigpharma M&A activity
3.2 Bigpharma partnering
Chapter 4 - Top bigpharma deals by value
4.1 Bigpharma M&A
4.2 Bigpharma partnering
Chapter 5 - Submitting Opportunities to Bigpharma
5.1 How to submit an opportunity
5.2 Opportunity submission template
5.3 Sending emails
5.4 Face to face at partnering events
5.5 Online submission forms
Chapter 6 - Forthcoming bigpharma partnering events
6.1 Forthcoming events
Chapter 7 - Bigpharma company - therapy locator
7.1 How to use the therapy matrix tables
7.2 Therapeutic area definitions
7.3 Bigpharma - Therapeutic target matrix - marketed and pipeline compounds
7.4 Bigpharma - Therapeutic target matrix - expressed partnering interests
7.5 Bigpharma - Therapeutic target matrix - recent deals - 2005-2009
Chapter 8 - Bigpharma Company Profiles
8.1 How to use company profiles
8.2 Field definitions
8.3 Company profiles
Abbott
Actavis
Alcon Labs
Allergan
Amgen
Astellas
AstraZeneca
Baxter This brochure is published by Wildwood Ventures Ltd.
© 2010 - CurrentPartnering, a division of Wildwood Ventures Limited.
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Cephalon
Chugai
CSL
Daiichi Sankyo
Dainnipon Sumitomo
Eisai
Eli Lilly
Forest Laboratories
Genentech
Genzyme
Gilead Sciences
GlaxoSmithKline
Hospira
Johnson & Johnson
Lundbeck
Menarini
Merck & Co
Merck Serono
Mitsubishi-Tanabe
Mylan
Novartis
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Procter & Gamble
Ratiopharm
Roche
Sanofi-Aventis
Schering Plough
Servier
Shire
Solvay
Takeda
Teva
UCB
Watson
Wyeth
Chapter 9 - Resources
Appendices
Appendix 1 - Example contract document
About CurrentPartnering
Recent titles from CurrentPartnering
Order Form - Reports
Order Form - Partnering Agreements Company Profiles 2010
Table of figures
Figure 1: Bigpharma - top 50 by pharma sales
Figure 2: Leading Bigpharma M&A companies, 2005-2009
Figure 3: Bigpharma M&A activity - top 50 by pharma sales
Figure 4: Leading Bigpharma partnering companies, 2005-2009
Figure 5: Bigpharma partnering activity - top 50 by pharma sales
Figure 6: Leading M&A deals involving bigpharma by value, 2005-2009
Figure 7: Leading partnering deals by value, 2005-2009
Figure 8: Typical partnering opportunity submission template
Figure 10: Therapeutic area definitions 36
Figure 11: Therapeutic target matrix - marketed and pipeline compounds
Figure 12: Therapeutic target matrix - expressed partnering interests
Figure 12: Therapeutic target matrix - recent deals 2005-2009
Figure 14: Company profile template and definitions used in report
Figure 15: Abbott - Dealmaking frequency 2000-2009
Figure 16: Abbott - recent deals (2005-2009) by deal type
Figure 17: Abbott - recent deals (2005 - 2009) by stage of development
Figure 18: Abbott - recent deals (2005 - 2009) by therapy area
Figure 19: Recent Abbott partnering deals (2003-2009) where contract document available
Figure 20: Actavis - Dealmaking frequency 2000-2009
Figure 21: Actavis - recent deals (2005-2009) by deal type
Figure 22: Actavis - recent deals (2005 - 2009) by stage of development
Figure 23: Actavis - recent deals (2005 - 2009) by therapy area
Figure 24: Recent Actavis partnering deals (2003-2009) where contract document available
Figure 25: Alcon Labs dealmaking frequency 2000-2009
Figure 26: Alcon Labs - recent deals (2005 - 2009) by deal type
Figure 27: Alcon Labs - recent deals (2005 - 2009) by stage of development
Figure 28: Alcon Labs - recent deals (2005 - 2009) by therapy area
Figure 29: Recent Alcon Labs partnering deals (2003-2009) where contract document available
Figure 30: Allergan - Dealmaking frequency 2000-2009
Figure 31: Allergan - recent deals (2005-2009) by deal type
Figure 32: Allergan - recent deals (2005 - 2009) by stage of development
Figure 33: Allergan - recent deals (2005 - 2009) by therapy area
Figure 34: Recent Allergan partnering deals (2003-2009) where contract document available
Figure 35: Amgen - Dealmaking frequency 2000-2009
Figure 36: Amgen - recent deals (2005-2009) by deal type
Figure 37: Amgen - recent deals (2005 - 2009) by stage of development
Figure 38: Amgen - recent deals (2005 - 2009) by therapy area
Figure 39: Recent Amgen partnering deals (2003-2009) where contract document available
Figure 40: Astellas - Dealmaking frequency 2000-2009
Figure 41: Astellas - recent deals (2005-2009) by deal type
Figure 42: Astellas - recent deals (2005 - 2009) by stage of development
Figure 43: Astellas - recent deals (2005 - 2009) by therapy area
Figure 44: Recent Astellas partnering deals (2003-2009) where contract document available
Figure 45: AstraZeneca - Dealmaking frequency 2000-2009
Figure 46: AstraZeneca - recent deals (2005-2009) by deal type
Figure 47: AstraZeneca - recent deals (2005 - 2009) by stage of development
Figure 48: AstraZeneca - recent deals (2005 - 2009) by therapy area
Figure 49: Recent AstraZeneca partnering deals (2003-2009) where contract document available
Figure 50: Baxter - Dealmaking frequency 2000-2009
Figure 51: Baxter - recent deals (2005-2009) by deal type
Figure 52: Baxter - recent deals (2005 - 2009) by stage of development
Figure 53: Baxter - recent deals (2005 - 2009) by therapy area
Figure 54: Recent Baxter partnering deals (2003-2009) where contract document available
Figure 55: Bayer - Dealmaking frequency 2000-2009
Figure 56: Bayer - recent deals (2005-2009) by deal type
Figure 57: Bayer - recent deals (2005 - 2009) by stage of development
Figure 58: Bayer - recent deals (2005 - 2009) by therapy area
Figure 59: Recent Bayer partnering deals (2003-2009) where contract document available
Figure 60: Biogen Idec - Dealmaking frequency 2000-2009
Figure 61: Biogen Idec - recent deals (2005 - 2009) by deal type
Figure 62: Biogen Idec - recent deals (2005 - 2009) by stage of development
Figure 63: Biogen Idec - recent deals (2005 - 2009) by therapy area
Figure 64: Recent Biogen Idec partnering deals (2003-2009) where contract document available
Figure 65: Boehringer Ingelheim - Dealmaking frequency 2000-2009
Figure 66: Boehringer Ingelheim - recent deals (2005 - 2009) by deal type
Figure 67: Boehringer Ingelheim - recent deals (2005 - 2009) by stage of development
Figure 68: Boehringer Ingelheim - recent deals (2005 - 2009) by therapy area
Figure 69: Recent Boehringer Ingelheim partnering deals (2003-2009) where contract document available
Figure 70: Bristol-Myers Squibb - Dealmaking frequency 2000-2009
Figure 71: Bristol-Myers Squibb - recent deals (2005 - 2009) by deal type
Figure 72: Bristol-Myers Squibb - recent deals (2005 - 2009) by stage of development
Figure 73: Bristol-Myers Squibb - recent deals (2005 - 2009) by therapy area
Figure 74: Recent Bristol-Myers Squibb partnering deals (2003-2009) where contract document available
Figure 75: Cephalon - Dealmaking frequency 2000-2009
Figure 76: Cephalon - recent deals (2005-2009) by deal type
Figure 77: Cephalon - recent deals (2005 - 2009) by stage of development
Figure 78: Cephalon - recent deals (2005 - 2009) by therapy area
Figure 79: Recent Cephalon partnering deals (2003-2009) where contract document available
Figure 80: Chugai - Dealmaking frequency 2000-2009
Figure 81: Chugai - recent deals (2005-2009) by deal type
Figure 82: Chugai - recent deals (2005 - 2009) by stage of development
Figure 83: Chugai - recent deals (2005 - 2009) by therapy area
Figure 84: Recent Chugai partnering deals (2003-2009) where contract document available
Figure 85: CSL - Dealmaking frequency 2000-2009
Figure 86: CSL - recent deals (2005-2009) by deal type
Figure 87: CSL - recent deals (2005 - 2009) by stage of development
Figure 88: CSL - recent deals (2005 - 2009) by therapy area
Figure 89: Recent CSL partnering deals (2003-2009) where contract document available
Figure 90: DaiichiSankyo - Dealmaking frequency 2000-2009
Figure 91: DaiichiSankyo - recent deals (2005-2009) by deal type
Figure 92: DaiichiSankyo - recent deals (2005 - 2009) by stage of development
Figure 93: DaiichiSankyo - recent deals (2005 - 2009) by therapy area
Figure 94: Recent DaiichSankyo partnering deals (2003-2009) where contract document available
Figure 95: Dainippon Sumitomo - Dealmaking frequency 2000-2009
Figure 96: Dainippon Sumitomo - recent deals (2005-2009) by deal type
Figure 97: Dainippon Sumitomo - recent deals (2005 - 2009) by stage of development
Figure 98: Dainippon Sumitomo - recent deals (2005 - 2009) by therapy area
Figure 99: Recent Dainippon Sumitomo partnering deals (2003-2009) where contract document available
Figure 100: Eisai - Dealmaking frequency 2000-2009
Figure 101: Eisai - recent deals (2005-2009) by deal type
Figure 102: Eisai - recent deals (2005 - 2009) by stage of development
Figure 103: Eisai - recent deals (2005 - 2009) by therapy area
Figure 104: Recent Eisai partnering deals (2003-2009) where contract document available
Figure 105: Eli Lilly - Dealmaking frequency 2000-2009
Figure 106: Eli Lilly - recent deals (2005-2009) by deal type
Figure 107: Eli Lilly - recent deals (2005 - 2009) by stage of development
Figure 108: Eli Lilly - recent deals (2005 - 2009) by therapy area
Figure 109: Recent Eli Lilly partnering deals (2003-2009) where contract document available
Figure 110: Forest - Dealmaking frequency 2000-2009
Figure 111: Forest - recent deals (2005-2009) by deal type
Figure 112: Forest - recent deals (2005 - 2009) by stage of development
Figure 113: Forest - recent deals (2005 - 2009) by therapy area
Figure 114: Recent Forest partnering deals (2003-2009) where contract document available Figure 115: Genentech - Dealmaking frequency 2000-2009
Figure 116: Genentech - recent deals (2005-2009) by deal type
Figure 117: Genentech - recent deals (2005 - 2009) by stage of development
Figure 118: Genentech - recent deals (2005 - 2009) by therapy area
Figure 119: Recent Genentech partnering deals (2003-2009) where contract document available
Figure 120: Genzyme - Dealmaking frequency 2000-2009
Figure 121: Genzyme - recent deals (2005-2009) by deal type
Figure 122: Genzyme - recent deals (2005 - 2009) by stage of development
Figure 123: Genzyme - recent deals (2005 - 2009) by therapy area
Figure 124: Recent Genzyme partnering deals (2003-2009) where contract document available
Figure 125: Gilead - Dealmaking frequency 2000-2009
Figure 126: Gilead - recent deals (2005-2009) by deal type
Figure 127: Gilead - recent deals (2005 - 2009) by stage of development
Figure 128: Gilead - recent deals (2005 - 2009) by therapy area
Figure 129: Recent Gilead partnering deals (2003-2009) where contract document available
Figure 130: GlaxoSmithKline - Dealmaking frequency 2000-2009
Figure 131: GlaxoSmithKline - recent deals (2005-2009) by deal type
Figure 132: GlaxoSmithKline - recent deals (2005 - 2009) by stage of development
Figure 133: GlaxoSmithKline - recent deals (2005 - 2009) by therapy area
Figure 134: Recent GlaxoSmithKline partnering deals (2003-2009) where contract document available
Figure 135: Hospira - Dealmaking frequency 2000-2009
Figure 136: Hospira - recent deals (2005-2009) by deal type
Figure 137: Hospira - recent deals (2005 - 2009) by stage of development
Figure 138: Hospira - recent deals (2005 - 2009) by therapy area
Figure 139: Recent Hospira partnering deals (2003-2009) where contract document available
Figure 140: Johnson & Johnson - Dealmaking frequency 2000-2009
Figure 141: Johnson & Johnson - recent deals (2005-2009) by deal type
Figure 142: Johnson & Johnson - recent deals (2005 - 2009) by stage of development
Figure 143: Johnson & Johnson - recent deals (2005 - 2009) by therapy area
Figure 144: Recent Johnson & Johnson partnering deals (2003-2009) where contract document available
Figure 145: Lundbeck - Dealmaking frequency 2000-2009
Figure 146: Lundbeck - recent deals (2005-2009) by deal type
Figure 147: Lundbeck - recent deals (2005 - 2009) by stage of development
Figure 148: Lundbeck - recent deals (2005 - 2009) by therapy area
Figure 149: Recent Lundbeck partnering deals (2003-2009) where contract document available
Figure 150: Menarini - Dealmaking frequency 2000-2009
Figure 151: Menarini - recent deals (2005-2009) by deal type
Figure 152: Menarini - recent deals (2005 - 2009) by stage of development
Figure 153: Menarini - recent deals (2005 - 2009) by therapy area
Figure 154: Recent Menarini partnering deals (2003-2009) where contract document available
Figure 155: Merck & Co - Dealmaking frequency 2000-2009
Figure 156: Merck & Co - recent deals (2005-2009) by deal type
Figure 157: Merck & Co - recent deals (2005 - 2009) by stage of development
Figure 158: Merck & Co - recent deals (2005 - 2009) by therapy area
Figure 159: Recent Merck & Co partnering deals (2003-2009) where contract document available
Figure 160: Merck KGaA - Dealmaking frequency 2000-2009
Figure 161: Merck KGaA - recent deals (2005-2009) by deal type
Figure 162: Merck KGaA - recent deals (2005 - 2009) by stage of development
Figure 163: Merck KGaA - recent deals (2005 - 2009) by therapy area
Figure 164: Recent Merck KGaA partnering deals (2003-2009) where contract document available
Figure 165: Mitsubishi-Tanabe - Dealmaking frequency 2000-2009
Figure 166: Mitsubishi-Tanabe - recent deals (2005-2009) by deal type
Figure 167: Mitsubishi-Tanabe - recent deals (2005 - 2009) by stage of development
Figure 168: Mitsubishi-Tanabe - recent deals (2005 - 2009) by therapy area
Figure 169: Recent Mitsubishi-Tanabe partnering deals (2003-2009) where contract document available
Figure 170: Mylan - Dealmaking frequency 2000-2009
Figure 171: Mylan - recent deals (2005-2009) by deal type
Figure 172: Mylan - recent deals (2005 - 2009) by stage of development
Figure 173: Mylan - recent deals (2005 - 2009) by therapy area Figure 174: Recent Mylan partnering deals (2003-2009) where contract document available
Figure 175: Novartis - Dealmaking frequency 2000-2009
Figure 176: Novartis - recent deals (2005-2009) by deal type
Figure 177: Novartis - recent deals (2005 - 2009) by stage of development
Figure 178: Novartis - recent deals (2005 - 2009) by therapy area
Figure 179: Recent Novartis partnering deals (2003-2009) where contract document available
Figure 180: Novo Nordisk - Dealmaking frequency 2000-2009
Figure 181: Novo Nordisk - recent deals (2005-2009) by deal type
Figure 182: Novo Nordisk - recent deals (2005 - 2009) by stage of development
Figure 183: Novo Nordisk - recent deals (2005 - 2009) by therapy area
Figure 184: Recent Novo Nordisk partnering deals (2003-2009) where contract document available
Figure 185: Nycomed - Dealmaking frequency 2000-2007
Figure 186: Nycomed - recent deals (2005-2008) by deal type
Figure 187: Nycomed - recent deals (2005 - 2009) by stage of development
Figure 188: Nycomed - recent deals (2005 - 2009) by therapy area
Figure 189: Recent Nycomed partnering deals (2003-2009) where contract document available
Figure 190: Otsuka - Dealmaking frequency 2000-2009
Figure 191: Otsuka - recent deals (2005-2009) by deal type
Figure 192: Otsuka - recent deals (2005 - 2009) by stage of development
Figure 193: Otsuka - recent deals (2005 - 2009) by therapy area
Figure 194: Recent Otsuka partnering deals (2003-2009) where contract document available
Figure 195: Pfizer - Dealmaking frequency 2000-2009
Figure 196: Pfizer - recent deals (2005-2009) by deal type
Figure 197: Pfizer - recent deals (2005 - 2009) by stage of development
Figure 198: Pfizer - recent deals (2005 - 2009) by therapy area
Figure 199: Recent Pfizer partnering deals (2003-2009) where contract document available
Figure 200: Procter & Gamble - Dealmaking frequency 2000-2009
Figure 201: Procter & Gamble - recent deals (2005-2009) by deal type
Figure 202: Procter & Gamble - recent deals (2005 - 2009) by stage of development
Figure 203: Procter & Gamble - recent deals (2005 - 2009) by therapy area
Figure 204: Recent Procter & Gamble partnering deals (2003-2009) where contract document available
Figure 205: Ratiopharm - Dealmaking frequency 2000-2009
Figure 206: Ratiopharm - recent deals (2005-2009) by deal type
Figure 207: Ratiopharm - recent deals (2005 - 2009) by stage of development
Figure 208: Ratiopharm - recent deals (2005 - 2009) by therapy area
Figure 209: Recent Ratiopharm partnering deals (2003-2009) where contract document available
Figure 210: Roche - Dealmaking frequency 2000-2009
Figure 211: Roche - recent deals (2005-2009) by deal type
Figure 212: Roche - recent deals (2005 - 2009) by stage of development
Figure 213: Roche - recent deals (2005 - 2009) by therapy area
Figure 214: Recent Roche partnering deals (2003-2009) where contract document available
Figure 215: Sanofi-Aventis - Dealmaking frequency 2000-2009
Figure 216: Sanofi-Aventis - recent deals (2005-2009) by deal type
Figure 217: Sanofi-Aventis - recent deals (2005 - 2009) by stage of development
Figure 218: Sanofi-Aventis - recent deals (2005 - 2009) by therapy area
Figure 219: Recent Sanofi-Aventis partnering deals (2003-2009) where contract document available
Figure 219: Schering Plough - Dealmaking frequency 2000-2009
Figure 220: Schering Plough - recent deals (2005-2009) by deal type
Figure 221: Schering Plough - recent deals (2005 - 2009) by stage of development
Figure 222: Schering Plough - recent deals (2005 - 2009) by therapy area
Figure 223: Recent Schering Plough partnering deals (2003-2009) where contract document available
Figure 225: Servier - Dealmaking frequency 2000-2009
Figure 226: Servier - recent deals (2005-2009) by deal type
Figure 227: Servier - recent deals (2005 - 2009) by stage of development
Figure 228: Servier - recent deals (2005 - 2009) by therapy area
Figure 229: Recent Servier partnering deals (2003-2009) where contract document available
Figure 230: Shire - Dealmaking frequency 2000-2009
Figure 231: Shire - recent deals (2005-2009) by deal type
Figure 232: Shire - recent deals (2005 - 2009) by stage of development Figure 233: Shire - recent deals (2005 - 2009) by therapy area
Figure 234: Recent Shire partnering deals (2003-2009) where contract document available
Figure 235: Solvay - Dealmaking frequency 2000-2009
Figure 236: Solvay - recent deals (2005-2009) by deal type
Figure 237: Solvay - recent deals (2005 - 2009) by stage of development
Figure 238: Solvay - recent deals (2005 - 2009) by therapy area
Figure 239: Recent Solvay partnering deals (2003-2009) where contract document available
Figure 240: Takeda - Dealmaking frequency 2000-2009
Figure 241: Takeda - recent deals (2005-2009) by deal type
Figure 242: Takeda - recent deals (2005 - 2009) by stage of development
Figure 243: Takeda - recent deals (2005 - 2009) by therapy area
Figure 244: Recent Takeda partnering deals (2003-2009) where contract document available
Figure 245: Teva - Dealmaking frequency 2000-2009
Figure 246: Teva - recent deals (2005-2009) by deal type
Figure 247: Teva - recent deals (2005 - 2009) by stage of development
Figure 248: Teva - recent deals (2005 - 2009) by therapy area
Figure 249: Recent Teva partnering deals (2003-2009) where contract document available
Figure 250: UCB Group - Dealmaking frequency 2000-2009
Figure 251: UCB Group - recent deals (2005-2009) by deal type
Figure 252: UCB Group - recent deals (2005 - 2009) by stage of development
Figure 253: UCB Group - recent deals (2005 - 2009) by therapy area
Figure 254: Recent UCB Group partnering deals (2003-2009) where contract document available
Figure 255: Watson - Dealmaking frequency 2000-2009
Figure 256: Watson - recent deals (2005-2009) by deal type
Figure 257: Watson - recent deals (2005 - 2009) by stage of development
Figure 258: Watson - recent deals (2005 - 2009) by therapy area
Figure 259: Recent Watson partnering deals (2003-2009) where contract document available
Figure 260: Wyeth - Dealmaking frequency 2000-2009
Figure 261: Wyeth - recent deals (2005-2009) by deal type
Figure 262: Wyeth - recent deals (2005 - 2009) by stage of development
Figure 263: Wyeth - recent deals (2005 - 2009) by therapy area
Figure 264: Recent Wyeth partnering deals (2003-2009) where contract document available
Figure 265: Online partnering resources
Figure 266: Collaborative R&D and license agreement between GlaxoSmithKline and Supergen, November 2009